Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

DA Davidson Maintains Buy on Xos, Lowers Price Target to $13

DA Davidson analyst Michael Shlisky maintains Xos (NASDAQ:XOS) with a Buy and lowers the price target from $15 to $13.

byBenzinga Newsdesk

November 12, 2021

1 minute read

DA Davidson analyst Michael Shlisky maintains Xos (NASDAQ:XOS) with a Buy and lowers the price target from $15 to $13.

Raymond James Maintains Outperform on Brinker International, Lowers Price Target to $67.5

By Benzinga Newsdesk

Today, 10:06 PM

Raymond James analyst Brian Vaccaro maintains Brinker International (NYSE:EAT) with a Outperform and lowers the price target from $75 to $67.5.

EAT

Trulieve Teams Up With Connected Cannabis & AlienLabs

By Vuk Zdinjak

Today, 10:06 PM

Trulieve Cannabis Corp. (OTCQX: TCNNF) (CSE:TRUL) , entered into partnership with California-based Connected Cannabis and AlienLabs.

CSE:TRUL

Jefferies Upgrades Nordstrom to Buy, Raises Price Target to $24

By Benzinga Newsdesk

Today, 10:06 PM

Jefferies analyst Stephanie Wissink upgrades Nordstrom (NYSE:JWN) from Hold to Buy and raises the price target from $21 to $24.

JWN

Jasper Therapeutics Announces FDA Fast Track Designation For JSP191

By Bill Haddad

Today, 10:06 PM

JSP191 is currently being evaluated in four ongoing clinical studies in allogeneic hematopoietic stem cell transplant in patients with Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS), SCID, Fanconi

JSPR

DA Davidson Maintains Buy on Xos, Lowers Price Target to $13

Related Posts

Raymond James Maintains Outperform on Brinker International, Lowers Price Target to $67.5

Trulieve Teams Up With Connected Cannabis & AlienLabs

Jefferies Upgrades Nordstrom to Buy, Raises Price Target to $24

Jasper Therapeutics Announces FDA Fast Track Designation For JSP191